BioLineRx (NASDAQ:BLRX – Get Free Report) and Aadi Bioscience (NASDAQ:AADI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Analyst Recommendations
This is a summary of current ratings for BioLineRx and Aadi Bioscience, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLineRx | 0 | 1 | 1 | 0 | 2.50 |
| Aadi Bioscience | 0 | 5 | 0 | 0 | 2.00 |
BioLineRx currently has a consensus target price of $26.00, suggesting a potential upside of 881.13%. Aadi Bioscience has a consensus target price of $1.67, suggesting a potential upside of 1.63%. Given BioLineRx’s stronger consensus rating and higher probable upside, research analysts clearly believe BioLineRx is more favorable than Aadi Bioscience.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioLineRx | $21.99 million | 0.40 | -$60.61 million | ($8.80) | -0.30 |
| Aadi Bioscience | $25.07 million | 1.62 | -$65.76 million | ($2.35) | -0.70 |
BioLineRx has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
BioLineRx has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
Insider and Institutional Ownership
1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares BioLineRx and Aadi Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLineRx | -90.57% | -163.37% | -34.21% |
| Aadi Bioscience | -246.06% | -71.87% | -57.28% |
Summary
BioLineRx beats Aadi Bioscience on 8 of the 14 factors compared between the two stocks.
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
About Aadi Bioscience
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
